Regulation of parathyroid hormone mRNA stability by calcium, phosphate and uremia

2007 ◽  
Vol 16 (4) ◽  
pp. 305-310 ◽  
Author(s):  
Tally Naveh-Many ◽  
Morris Nechama
Author(s):  
Stefania Sella ◽  
Luciana Bonfante ◽  
Maria Fusaro ◽  
Flavia Neri ◽  
Mario Plebani ◽  
...  

AbstractObjectivesKidney transplant (KTx) recipients frequently have deficient or insufficient levels of serum vitamin D. Few studies have investigated the effect of cholecalciferol in these patients. We evaluated the efficacy of weekly cholecalciferol administration on parathyroid hormone (PTH) levels in stable KTx patients with chronic kidney disease stage 1–3.MethodsIn this retrospective cohort study, 48 stable KTx recipients (37 males, 11 females, aged 52 ± 11 years and 26 months post-transplantation) were treated weekly with oral cholecalciferol (7500–8750 IU) for 12 months and compared to 44 untreated age- and gender-matched recipients. Changes in levels of PTH, 25(OH) vitamin D (25[OH]D), serum calcium, phosphate, creatinine and estimated glomerular filtration rate (eGFR) were measured at baseline, 6 and 12 months.ResultsAt baseline, clinical characteristics were similar between treated and untreated patients. Considering the entire cohort, 87 (94.6%) were deficient in vitamin D and 64 (69.6%) had PTH ≥130 pg/mL. Serum calcium, phosphate, creatinine and eGFR did not differ between groups over the follow-up period. However, 25(OH)D levels were significantly higher at both 6 (63.5 vs. 30.3 nmol/L, p < 0.001) and 12 months (69.4 vs. 30 nmol/L, p < 0.001) in treated vs. untreated patients, corresponding with a significant reduction in PTH at both 6 (112 vs. 161 pg/mL) and 12 months (109 vs. 154 pg/mL) in treated vs. untreated patients, respectively (p < 0.001 for both).ConclusionsWeekly administration of cholecalciferol can significantly and stably reduce PTH levels, without any adverse effects on serum calcium and renal function.


Author(s):  
Almandlawi S G ◽  
Ahmed A S

Introduction: This study aims to assess the status of serum vitamin D, parathyroid hormone, type II collagen, calcium, phosphate,albumin, and alkaline phosphatase in osteoarthritis and rheumatoidarthritis patients and to study their association with rheumatoid arthritis disease activity. Materials and Methods: This prospectivecross-sectional study was conducted at the clinical analysis department, College of Pharmacy, Hawler Medical University in 2017.They study samples were collected at Rizgary Teaching Hospitalduring the period September 2015 to January 2016. A total of(N=156) participants were included: (N=53) patients with rheumatoid arthritis (RA), (N=53) with osteoarthritis (OA), and (N=50)healthy controls. Enzyme Linked Immuno Sorbent Assay kits determined serum vitamin D, parathyroid hormone, and type II collagen; and serum albumin, calcium, phosphate and alkaline phosphatase, were determined by standard colorimetric methods. Resultsand Discussion: Statistically significant higher levels of parathyroid hormone and type II collagen, with lower levels of Vitamin D,were found in the osteoarthritis group than the rheumatoid arthritisgroup and the healthy controls (P=0.007, P<0.001, P= 0.005) respectively. Multiple linear regression showed a statistically significant difference in serum type II collagen as a dependent variable, inpatients suffering from RA or OA compared to the healthy controlgroup; after adjusting for the effect of other independent studyvariables, there was a mean increase of (45.90 nmol/L, P<0.001)in RA patients, and OA patients showed greater levels of type IIcollagen (73.950 nmol/L) than the health control group (P<0.001).Conclusions: Elevated type II collagen levels, in conjunction witha low vitamin D status, may be strong discriminator between osteoarthritis and rheumatoid arthritis patients.


1981 ◽  
Vol 241 (3) ◽  
pp. F263-F272 ◽  
Author(s):  
R. F. Wideman ◽  
E. J. Braun

Phosphate buffers (ammonium, sodium, potassium, and calcium phosphate, pH 5.5, 7.2, 8.5) and 32P were infused unilaterally into the renal portal systems of intact, parathyroidectomized (PTX), and parathyroid hormone-infused (PTH) domestic fowl to study the secretory flux for inorganic phosphate (Pi). Urine samples were collected simultaneously from both kidneys, with the uninfused kidney serving as a control for the portal-perfused kidney (modified Sperber technique). No consistent unilateral excess of Pi or 32P excretion occurred for any of the experimental groups. For intact birds, fractional 32P excretion by both kidneys (FE32p) was identical to fractional Pi excretion (FEpi) (determined by chemical analysis) and reflected net reabsorption (0.64). However, during PTH infusion, FE32p was 0.82 (net reabsorption) while FEPi was 1.21 (net secretion). These results indicate that a) the peritubular-to-lumen flux for Pi and 32P is a minor component of net tubular transport, regardless of the parathyroid status, counterion availability, or peritubular Pi concentration; b) plasma Pi and 32P enter the tubule lumen predominantly by filtration; c) PTH stimulates tubular Pi secretion; and d) the secreted Pi is derived from an organic or inorganic pool that does not readily equilibrate with infused 32P (or presumably peritubular Pi).


Author(s):  
Patrick Biggar ◽  
Hansjörg Rothe ◽  
Markus Ketteler

Chronic kidney disease-mineral and bone disorders (CKD-MBD), calcium, phosphate, and parathyroid hormone are biomarkers of mortality and cardiovascular risk. Hyperphosphataemia is a prominent and pathophysiologically most plausible risk indicator. Calcium balance and load appear to be more important than serum concentrations. Parathyroid hormone is a less reliable marker with a relatively wide range extending above that applicable for a normal population especially when used as a singular laboratory parameter without additional assessment of bone metabolism, for example, bone-specific alkaline phosphatase and bone biopsy. There is not a single prospective controlled hard-outcome study that provides us with unequivocal evidence that such an isolated laboratory parameter-based treatment approach will lead to significant clinical improvements. As CKD-MBD is complex, clinical decisions would be made easier by informative prospective trials.


1978 ◽  
Vol 6 (4) ◽  
pp. 342-349 ◽  
Author(s):  
A. M. S. Black

Thirteen of sixteen patients with acute renal failure and requiring respiratory and other supportive treatment in an intensive care area became hypercalcaemic whilst still receiving haemodialysis. Results of calcium, phosphate and parathyroid hormone estimations are presented and their disturbances in acute renal failure are discussed.


2013 ◽  
Vol 37 (4) ◽  
pp. 339-345 ◽  
Author(s):  
Thomas F. Hiemstra ◽  
Adam J.D. Brown ◽  
Afzal N. Chaudhry ◽  
Michael Walsh

2011 ◽  
Vol 20 (1) ◽  
pp. 85-89 ◽  
Author(s):  
S.M. Deger ◽  
R. Mutluay ◽  
U. Derici ◽  
F. Mandiralioglu ◽  
T. Arinsoy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document